Kazia Therapeutics Limited, formerly Novogen Limited, incorporated on March 18, 1994, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company’s product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company’s target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma.Cantrixil (TRX-E-002-1)Cantrixil is the lead development candidate arising from its SBP technology. Cantrixil has been designed to be injected into the peritoneal cavity with the focus of inducing cell death in both differentiated cancer cells and cancer initiating cells, those cells thought to be primarily responsible for cancer recurrence post chemotherapy. The Company focuses on the Phase I study of intra-peritoneal Cantrixil to assess its pharmacokinetics in patients with refractory or recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
|Bank Name||Kazia Therapeutics Limited|
|CEO||Dr. James Garner M.A.|